Your answer arrived quickly.
Problem with BT approval is that if it is not gained, we will likely never know as they have not announced that they applied.
So those sweating on it (I am one) will just have to hang on in the hope that it comes soon, as the longer the wait becomes, the greater the probability that it has been refused.
- Forums
- ASX - By Stock
- NEU
- Share Price
NEU
neuren pharmaceuticals limited
Add to My Watchlist
3.00%
!
$13.24

Share Price, page-15362
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.24 |
Change
0.385(3.00%) |
Mkt cap ! $1.652B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.92 | $4.382M | 334.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 214 | $13.23 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.24 | 741 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 187 | 13.230 |
5 | 399 | 13.220 |
3 | 554 | 13.210 |
10 | 2227 | 13.200 |
6 | 1852 | 13.190 |
Price($) | Vol. | No. |
---|---|---|
13.240 | 665 | 13 |
13.250 | 2297 | 22 |
13.260 | 2298 | 14 |
13.270 | 1620 | 9 |
13.280 | 2926 | 7 |
Last trade - 12.32pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online